17β-Estradiol Cell Integration for Preserved Epithelial Tissue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for integrating cells into epithelial tissue often destroy existing cells and lack the ability to integrate heterologous or genetically altered cells without causing adverse immunological reactions.
Innovation Solution
A combination of compositions comprising 17β-estradiol and a cell suspension is used, where 17β-estradiol is applied to loosen the epithelial layer, followed by the cell suspension to integrate cells into the tissue, maintaining the original tissue integrity and viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing methods for integrating cells into epithelial tissue are used, then cell integration can be achieved, but existing cells are destroyed and tissue integrity is compromised
Solution Approach 1:
The patent applies parameter changes by using 17β-estradiol to temporarily alter the permeability and structural parameters of the epithelial layer, creating transient gaps that allow cell integration without destruction. The hormone modifies the tight junction parameters and cell adhesion properties, enabling integration while preserving overall tissue integrity.
Solution Approach 2:
17β-estradiol serves as an intermediary substance that mediates between the integrating cells and the epithelial tissue. It temporarily modifies the epithelial barrier properties to facilitate cell integration, then is removed, allowing the tissue to restore its original integrity while maintaining the integrated cells.
2Adaptability or versatility
If heterologous or genetically altered cells are integrated into epithelium, then therapeutic effects can be achieved, but adverse immunological reactions occur
Solution Approach 1:
The patent applies preliminary action by using 17β-estradiol to pre-condition the epithelial tissue before cell integration. This preliminary hormonal treatment modifies the tissue environment to be more receptive to heterologous cells, potentially reducing immunological rejection by altering cell surface properties and reducing inflammatory responses in advance.
3Reliability
If cell integration is performed without destroying existing cells, then tissue integrity is maintained, but the integration process becomes more difficult
Solution Approach 1:
The patent applies periodic action through the temporary, reversible application of 17β-estradiol. The hormone is applied for a specific duration to create integration-friendly conditions, then removed to allow tissue recovery. This periodic hormonal modulation temporarily eases the integration difficulty while preserving tissue integrity throughout the process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively integrates cells into the epithelial tissue, forming a closed layer with adherens junctions within 2 to 10 hours, without significant edema or cell destruction, and is suitable for in vivo and extracorporeal applications.
Implementation Method 1
10 nM 17β-estradiol increases the permeability for FITC-labelled dextran of a cultivated monolayer of endothelial cells
Implementation Method 2
17β-estradiol in a dose-dependent manner increases endothelial cell volume, apical cell surface and cell elasticity in HUVEC
Data Source
Figure 1A~1D
Figure 2A~2B
AI summary
The invention provides a combination of compositions comprising in a first composition 17β-estradiol as the active ingredient and, as a second composition, a suspension of cells for use in the treatment of functional defects of an epithelium, e.g. of an epithelium of a tissue, which tissue may be part of an organ.